The global bipolar disorder market is growing at a significant CAGR of around 2.7% during the forecast period (2019-2025). The major factors that are primarily driving the growth of the market include the increased workplace stress, emerging awareness regarding the management of mental disorders, and growing insurance claims for mental health. According to the World Health Organization (WHO), almost 83 million people are affected annually by mental disorders among the adult population of Europe (aged 18-65), where female rates are higher than males. This involves the high demand for products which can bring down the level of stress and bipolar disorder among people. In addition, there are various organizations and educational institutions such as ALAS Pro Salud Mental and Stanford University that have taken immense steps to spread awareness programs. These programs are assisting individuals to notice behavior change and other stress-related symptoms in their daily lives on accounts of which the demand for bipolar disorder treatment is increasing.

Additionally, there are bipolar disorder management apps available in the market, which include T2 mood tracker and eMoods. These apps are based on cognitive-behavioral therapy and are designed to address bipolar disorder at a gradual pace and offer ways for the appropriate management of stress. For instance, MoodTracker.com is a simple web app that enables to track key health measurements, such as water intake, anxiety levels, depression, and sleep, among others. It maintains track of medications, exercises, and supplements and allows tracking any change in the treatment with complete history. It supports depressed and bipolar users to manage their condition with careful journaling and tracking their moods.

Segmental Outlook  

The bipolar disorder market is classified on the basis of type, treatment, and mechanism of action. Based on type, the market is segmented into bipolar disorder I, bipolar disorder II, and others. Based on the treatment, the market is bifurcated into drugs & medications and therapy & devices/apps. The drugs & medications segment is further segmented into anticonvulsants, antidepressants, antipsychotics, and others. Based on mechanism of action, the market is segmented into selective serotonin reuptake inhibitors (SSRIs), serotonin-norepinephrine reuptake inhibitors (SNRIs), benzodiazepines, beta blockers, and others.

Global Bipolar Disorder Market Share by Treatment, 2018 (%)

Drugs & medications dominates the global bipolar disorder market

Drugs & medications are majorly used treatment procedure adopted for bipolar disorder patients. Hospitals and clinics are the first places referred to such patients, and doctors mainly prescribe drugs for the initial level of bipolar disorder. Along with this, there is a lack of awareness of stress-reducing wearables and therapies in emerging economies, such as India and China. These factors, in turn, drive the adoption rate of drugs & medications for the treatment of bipolar disorder. There are several drugs available for the treatment of bipolar disorder, which includes antidepressants, antipsychotics, and anticonvulsants. Antipsychotics are primarily used for the treatment of psychotic disorders, such as schizophrenia, bipolar disorder, and depression. These drugs are intended to relieve several neurological symptoms, including hallucinations in highly disturbed or aggressive patients. Zeldox (ziprasidone) ZELDOX is used for the treatment of symptoms of schizophrenia and associated psychotic disorders, and symptoms of mixed episodes or acute manic linked with bipolar disorder.

Regional Outlook 

The global bipolar disorder market is classified on the basis of geography, which includes North America, Europe, Asia-Pacific, and Rest of the World. Europe contributes a significant share in the bipolar disorder market due to the government programs and initiatives towards awareness of mental health disorders coupled with high cases of depression, anxiety and bipolar disorder in the region. According to the IHME, in Western Europe, there was a 3.92% share of the total population suffering from depression, 5.71% of the total population had an anxiety disorder and 0.94 % share of the population have bipolar disorder in 2017. Therefore, this significant share of behavioral disorders in the region provides a substantial demand for bipolar disorder treatment that further contributes to market growth.

Global Bipolar Disorder Market Growth, by Region 2019-2025

Asia-Pacific is expected to propel with a considerable growth rate in the global market

Asia-Pacific is estimated to project a considerable CAGR in the global bipolar disorder market. Countries in Asia-Pacific that are contributing to the market growth include China, India, and Japan. The market in the region is largely driven by increasing workplace stress and the prevalence of various mental health disorders such as anxiety, depression, and others. Further, the rising investment and initiatives from the government of various emerging economies of Asia-Pacific such as China, India, Singapore, and South Korea along with many other economies towards the adoption of a healthy lifestyle tend to accelerate the market share of bipolar disorder in the region. For instance, in May 2018, the Government of India launched one of the most progressive initiatives named Ayushman Bharat Yojana, the country’s biggest healthcare initiative to date. It is one of the largest healthcare schemes in India; it will provide $7,000 health cover to 50 crore impoverished families in the country for various diseases including mental and central nervous system disorders as well.

Market Players Outlook

The key players in the bipolar disorder market are contributing significantly by providing advanced technology-based products and through expanding their geographical presence across the globe. The key players operating in the global bipolar disorder market include Allergan PLC, Otsuka Pharmaceutical Co., Ltd., Eli Lilly and Co., AstraZeneca PLC, and Johnson & Johnson Services, Inc. These market players adopt various strategies such as product launch, partnerships, collaborations, merger, and acquisitions to sustain a strong position in the market. For instance, in May 2019, Allergan PLC and Gedeon Richter Plc declared the US FDA approval for (cariprazine) expanded use of VRAYLAR for the treatment of depressive episodes associated with bipolar I disorder (bipolar depression) in adults. VRAYLAR is approved in the US for the treatment of manic or mixed episodes associated with bipolar I disorder in adults. It was discovered and co-developed by Gedeon Richter Plc and is licensed by Allergan, in the US and Canada.

The Report Covers

• Market value data analysis of 2018 and forecast to 2025.
• Annualized market revenues ($ million) for each market segment.
• Country-wise analysis of major geographical regions.
• Key companies operating in the global bipolar disorder market. Based on the availability of data, information related to pipeline products, and relevant news is also available in the report.
• Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
• Analysis of market-entry and market expansion strategies.
• Competitive strategies by identifying ‘who-stands-where’ in the market.